Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears ThermoGenesis' MarrowXpress

This article was originally published in Clinica

Executive Summary

The US FDA has cleared ThermoGenesis' MarrowXpress system, which isolates stem cells from bone marrow, for use in a clinical laboratory setting or during operations. The Rancho Cordova, California firm submitted a 510(k) application to the agency last month, but the FDA determined MarrowXpress was exempt from these requirements – instead it will be regulated as laboratory equipment labelled for a specific use. ThermoGenesis CE marked the product, which is based on its AutoXpress platform, for sale in Europe last month. Bone marrow-derived stem cells are used in clinical trials in areas including blood disorders, ischaemic heart disease, peripheral artery disease and diabetes, and in orthopaedic and vascular surgeries.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel